country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-B1164A

Copy Link Print Information

Bromopride hydrochloride

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Bromopride hydrochloride is a selective, irreversible, competitive, and orally active dopamine D2 receptor antagonist. Bromopride hydrochloride can pass through the blood-brain barrier, inhibit the vomiting center, and enhance gastrointestinal motility, exerting antiemetic and gastrointestinal motility effects. Bromopride hydrochloride antagonizes dopamine-mediated vomiting reflexes and promotes gastrointestinal smooth muscle contraction, and has no adverse effects on abdominal wall healing in rats with postoperative abdominal infection. Bromopride hydrochloride can be used for the study of digestive system diseases (such as gastric hypomotility, nausea and vomiting).

For research use only. We do not sell to patients.

CAS No.: 52423-56-0
Formula: C₁₄H₂₃BrClN₃O₂
Molecular Weight:380.71

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (272 KB)

Bromopride hydrochloride Chemical Structure

CAS No.: 52423-56-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

D₂ Receptor

All Dopamine Receptor Isoforms :

In Vitro

Axon regeneration assay: Bromopride hydrochloride (100 μM; 5 d) significantly promotes axon regeneration in a rat cortical neuron scratch injury model and reversed the inhibitory effect of chondroitin sulfate proteoglycan (CSPG) on axon growth^[1].
Metabolite analysis assay: Bromopride hydrochloride (10 μM; 4 h) can be metabolized into 20 metabolites in mouse, rat, rabbit, dog, monkey and human hepatocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Rat embryonic cortical neurons (21 DIV), mouse dorsal root ganglion (DRG) neurons
Concentration:

100 μM
Incubation Time:

5 days (cortical scrape); 24 hours (DRG)
Result:

Increased axon regeneration into the lesion area by ~1.6-fold compared to CSPG-treated controls in rat cortical cultures wounded at 21 DIV, as quantified by βIII-tubulin immunostaining and image analysis.
Enhanced total axon length per neuron in adult mouse DRG neurons cultured on CSPG-coated plates, demonstrating its ability to counteract CSPG-mediated growth inhibition.

In Vivo

Rat sexual behavior model: Bromopride (20-60 mg; intravenous injection; single dose) hydrochloride dose-dependently inhibited male rat mating behavior (such as prolonged post-ejaculation latency) and increased serum prolactin levels^[2].
Rat peritonitis model: Bromopride (1 mg/kg; subcutaneous injection; every 12 hours; 3/7 days) hydrochloride significantly reduced abdominal wall wound edema and fibrin deposition in Wistar rats with induced peritonitis 7 days after surgery, without affecting wound breaking strength^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats (90-120 days, 350-575 g) with induced peritoneal sepsis via cecal ligation/perforation + left colon resection/anastomosis^[3]
Dosage:

1 mg/kg Bromopride
Administration:

Subcutaneous injection every 12 h until euthanasia (postoperative day 3 or 7)
Result:

Reduced abdominal wall edema (p=0.041) and fibrin deposition (p=0.041) compared to controls (GC7) on day 7, with no significant difference in wound breaking strength. No adverse effects on survival or clinical signs (apathy, diarrhea) were observed.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 52423-56-0
Molecular Weight 380.71
Formula C₁₄H₂₃BrClN₃O₂
SMILES

O=C(C1=CC(Br)=C(C=C1OC)N)NCCN(CC)CC.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (3)

All

Sort by:

Journal Impact Factor

Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Naunyn Schmiedebergs Arch Pharmacol

Bromopride stimulates 5-HT4-serotonin receptors in the human atrium. [Abstract]

2025 Mar 17. PMID: 40095050
bioRxiv

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. [Abstract]

2026 Apr 18:2026.04.17.719256. PMID: 42039650

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lachi-Silva L, et al. Population pharmacokinetics of orally administrated bromopride: Focus on the absorption process. Eur J Pharm Sci. 2020 Jan 15;142:105081. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Bromopride hydrochloride

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Bromopride hydrochloride

Publications Citing Use of MedChemExpress (MCE) Bromopride hydrochloride

All Dopamine Receptor Isoforms

Biological Activity

Chemical Information

Publications (3)

Purity & Documentation

References

Calculators

Help & FAQs

Bromopride hydrochloride Related Classifications

HY-B1164A Related Classifications